noted that CUR can inhibit IL‐6‐inducible STAT3 phosphorylation in a dose‐ and time‐dependent manner, further suggesting its potential as a therapeutic agent for targeting the IL‐6/JAK/STAT3 pathway in treating SCLC (Yang et al. 2012). The gene discussed is IL6; the disease is small cell lung carcinoma.